

## Nuvocept™: Addressing a huge public health priority in the post-Roe world



- Recent Roe v. Wade development makes the need for highly effective birth control more urgent than ever. To address this need, ARSTAT develops the first-ever oral contraceptive for women with above-normal weight.
- Twenty million US women with elevated BMI search for reliable birth control. Hormonal contraceptives (pills, patches, and rings) do not work well in this population due to poor efficacy and troublesome side effects. The ARSTAT's lead product – Nuvocept™ – will return the pill to these women as a trusted and safe option.
- At the pre-IND meeting, the FDA recognized the unmet need, accepted Nuvocept efficacy and safety projections, confirmed its **Phase III-ready** status, and endorsed a pathway to an **unprecedented label for women with high BMI**. Protected by **seven US patents and an EU patent**, Nuvocept is < \$20M and 3.5 years away from FDA approval. Top experts consider Nuvocept a > \$2B/year US opportunity. Strong ex-US sales are also expected.
- The patents are authored by the Founder, Arkady Rubin, Ph.D., a 30-year pharma veteran (J&J, Pfizer), a co-inventor of Ortho Tri-Cyclen Lo, one of the best US pills with sales translated into \$1.8B/year in today's market.
- Nuvocept will be advanced by a highly experienced team with a strong track record in women's health.

## Other ARSTAT Products



- **Premring™ (Phase IIb asset)** – **First-in-category** vaginal ring for uterine fibroids & endometriosis (~14 million US women). Drug delivery directly to affected tissues could be a **breakthrough solution**. **Two US patents**
- **Enhanta™ (Phase IIb asset)**– **First-in-category** single non-hormonal therapy for painful and heavy menstrual periods (>25 million US women). A likely first-line for a common disorder. **Four US patents**
- **Ducept™ (Phase III-ready)**– **First brand** that meets the consensus criteria of an ideal oral contraceptive. A great product for >2 million US normal-weight pill users; **minimal R&D costs**. **A US patent and an EU patent**

## Current Funding Needs



- ARSTAT Pharmaceuticals is raising a \$1M bridge financing round (SAFE notes, \$20M Valuation Cap, 20% Discount) ahead of a pending private placement, followed by a firm-commitment IPO (1Q or 2Q of 2025). This round is deeply discounted relative to the expected IPO valuation (at least \$120M), offering exceptional near-term ROI.
- The company will use the proceeds to finalize the team and the BoD, conduct another pre-IND meeting, assemble one IND application, select vendors for the first pivotal study, and support the private placement.

## Business Model: Roadmap and Strategic Objectives



<b>1 Complete the \$1M bridge financing round</b> Continue R&D and support the private placement	<b>2 Possible IPO (near-term exit in ≈1 year): 5-6x ROI</b> \$120M+ valuation of a pending first-commitment IPO
<b>3 Complete planned programs (3-3.5 years)</b> Advance Nuvocept/Ducept up to the FDA approval. Enhanta is close to approval, Premring is in Phase III.	<b>4 EXIT (3.5 – 4 years): 25-30x ROI</b> Assuming <50% of the portfolio Net Present Value (NPV) after the completion of the planned R&D activities

**We are looking for executives (including a CEO and a Chairman of the Board)**

Please visit [www.arstatinfo.com](http://www.arstatinfo.com)  
or Contact:



**Arkady Rubin, PhD, Founder,  
President / CSO**  
E-mail: [arubin@arstatinc.com](mailto:arubin@arstatinc.com)  
Tel: (347)385-0878